Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

COVID-19 2Severe Acute Respiratory Syndrome 1Papillomavirus Infections 1Multiple Myeloma 1Mastocytosis 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypersensitivity 1

Interventions

Specimen Handling 7Radiotherapy, Intensity-Modulated 5Human Papillomavirus Recombinant Vaccine nonavalent 5Human Papillomavirus DNA Tests 5Colposcopy 5Cisplatin 5Patient Navigation 3Methods 3Early Intervention, Educational 3Carboplatin 3human papillomavirus vaccine, L1 type 16, 18 2epigallocatechin gallate 2artesunic acid 2artemisinin 2Standard of Care 2Practice Guidelines as Topic 2Papillomavirus Vaccines 2Mass Screening 2Educational Status 2Docetaxel 2Cytological Techniques 2Blood Specimen Collection 2Biopsy 2toripalimab 1fludarabine phosphate 1fludarabine 1artenimol 1aldesleukin 1adacel 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Papillomavirus Infections × 2019-nCoV Vaccine mRNA-1273 × 1 year × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡